NCT03329001 - Crossover Study to Assess the Relative Bioavailability and Bioequivalence of Niraparib Tablet Compared to Niraparib Capsule | Biotech Hunter

Enrollment

236

Participants

Timeline

Start Date

December 4, 2017

Primary Completion Date

December 30, 2021

Study Completion Date

June 15, 2023

Conditions

Neoplasms

Interventions

DRUG

Niraparib Tablet

Niraparib tablet formulation

DRUG

Niraparib Capsule

Niraparib capsule formulation

Trial Locations (16)

30322

GSK Investigational Site, Atlanta

34232

GSK Investigational Site, Sarasota

37203

GSK Investigational Site, Nashville

39216

GSK Investigational Site, Jackson

44106

GSK Investigational Site, Cleveland

45267

GSK Investigational Site, Cincinnati

49546

GSK Investigational Site, Grand Rapids

73104

GSK Investigational Site, Oklahoma City

75230

GSK Investigational Site, Dallas

77030

GSK Investigational Site, Houston

78229

GSK Investigational Site, San Antonio

80218

GSK Investigational Site, Denver

92024

GSK Investigational Site, Encinitas

92069

GSK Investigational Site, San Marcos

93720

GSK Investigational Site, Fresno

06520

GSK Investigational Site, New Haven

All Listed Sponsors

lead

Tesaro, Inc.

INDUSTRY